ABVC Biopharma Valuation
| ABVC Stock | USD 0.66 0.01 1.54% |
ABVC Biopharma is undervalued. ABVC Biopharma shows a prevailing Real Value of $0.97 per share. The current price of the entity is $0.66. Our model approximates the value of ABVC Biopharma from reviewing the entity fundamentals such as Operating Margin of 0.17 %, return on asset of -0.25, and Shares Owned By Insiders of 21.90 % as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting ABVC Biopharma's valuation include:
Price Book 1.8442 | Enterprise Value | Enterprise Value Ebitda (1.90) | Price Sales 30.576 | Enterprise Value Revenue 34.3914 |
Undervalued
Today
Please note that ABVC Biopharma's price fluctuation is abnormally volatile at this time. Calculation of the real value of ABVC Biopharma is based on 3 months time horizon. Increasing ABVC Biopharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since ABVC Biopharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of ABVC Stock. However, ABVC Biopharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.66 | Real 0.97 | Target 2.02 | Hype 0.66 | Naive 0.57 |
The real value of ABVC Stock, also known as its intrinsic value, is the underlying worth of ABVC Biopharma Company, which is reflected in its stock price. It is based on ABVC Biopharma's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of ABVC Biopharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of ABVC Biopharma helps investors to forecast how ABVC stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of ABVC Biopharma more accurately as focusing exclusively on ABVC Biopharma's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use ABVC Biopharma's intrinsic value based on its ongoing forecasts of ABVC Biopharma's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against ABVC Biopharma's closest peers. If more than one evaluation category is relevant for ABVC Biopharma we suggest using both methods to arrive at a better estimate.
ABVC Biopharma Cash |
|
ABVC Valuation Trend
Comparing ABVC Biopharma's enterprise value against its market capitalization is a good way to estimate the value of ABVC Biopharma uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
ABVC Biopharma Total Value Analysis
ABVC Biopharma is presently anticipated to have valuation of 17.53 M with market capitalization of 15.59 M, debt of 2.28 M, and cash on hands of 2.99 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the ABVC Biopharma fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
17.53 M | 15.59 M | 2.28 M | 2.99 M |
ABVC Biopharma Investor Information
About 22.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.84. Some equities with similar Price to Book (P/B) outperform the market in the long run. ABVC Biopharma recorded a loss per share of 0.81. The entity last dividend was issued on the 8th of May 2019. The firm had 1:10 split on the 25th of July 2023. Based on the key measurements obtained from ABVC Biopharma's financial statements, ABVC Biopharma is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April.ABVC Biopharma Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. ABVC Biopharma has an asset utilization ratio of 1.05 percent. This indicates that the Company is making $0.0105 for each dollar of assets. An increasing asset utilization means that ABVC Biopharma is more efficient with each dollar of assets it utilizes for everyday operations.ABVC Biopharma Ownership Allocation
ABVC Biopharma holds a total of 23.69 Million outstanding shares. ABVC Biopharma retains substantial amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the entity is less than the current market value, you may not be able to make money on it.ABVC Biopharma Profitability Analysis
The company reported the previous year's revenue of 152.43 K. Net Loss for the year was (10.52 M) with profit before overhead, payroll, taxes, and interest of 369.82 K.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates ABVC Biopharma's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in ABVC Biopharma and how it compares across the competition.
About ABVC Biopharma Valuation
The stock valuation mechanism determines ABVC Biopharma's current worth on a weekly basis. Our valuation model uses a comparative analysis of ABVC Biopharma. We calculate exposure to ABVC Biopharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of ABVC Biopharma's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -172 K | -163.4 K | |
| Pretax Profit Margin | (80.38) | (84.40) | |
| Operating Profit Margin | (61.99) | (65.09) | |
| Net Loss | (79.33) | (83.30) | |
| Gross Profit Margin | (0.88) | (0.93) |
ABVC Biopharma Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 4.3 M |
ABVC Biopharma Current Valuation Indicators
Valuation refers to the process of determining the present value of ABVC Biopharma and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value ABVC we look at many different elements of the entity such as ABVC's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as ABVC Biopharma, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use ABVC Biopharma's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes ABVC Biopharma's worth.Complementary Tools for ABVC Stock analysis
When running ABVC Biopharma's price analysis, check to measure ABVC Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ABVC Biopharma is operating at the current time. Most of ABVC Biopharma's value examination focuses on studying past and present price action to predict the probability of ABVC Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ABVC Biopharma's price. Additionally, you may evaluate how the addition of ABVC Biopharma to your portfolios can decrease your overall portfolio volatility.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |